AtriCure (ATRC) just kicked off a major clinical milestone by enrolling the first patient in its BoxX-NoAF trial. This FDA-approved study aims to test new device strategies for reducing atrial fibrillation after heart surgery.

Momentum has been quietly building for AtriCure, with its 90-day share price return of 14.9% and year-to-date gain nearing 20%. Recent news of its groundbreaking BoxX-NoAF trial has helped maintain positive sentiment. Although the stock moved slightly lower this week, investors who have held on over the past twelve months have enjoyed a 26.9% total shareholder return, highlighting renewed optimism compared to a softer long-term picture.

Curious what else is trending in healthcare? Take the next step and see the full list of opportunities with See the full list for free.

With shares trading at a sizable discount to analyst price targets, yet already showing strong gains this year, investors now face a key question: Is AtriCure undervalued or has the market already priced in future growth potential?

Most Popular Narrative: 27.1% Undervalued

Compared to the last close at $36.47, the narrative-backed fair value signals notable upside if the projected growth path holds true. This perspective sets the stage for a deeper look at the financial assumptions underneath bullish analyst expectations.

Rapid revenue growth is supported by accelerated adoption of AtriCure's innovative, minimally invasive devices like the AtriClip FLEX Mini and cryoSPHERE MAX. These products directly benefit from the global trend toward minimally invasive cardiac procedures and hospital prioritization of advanced surgical solutions, which increases both volumes and average selling prices and drives top-line expansion. Expanding access to international markets, including robust sales growth in Europe and Asia and continued investment in global commercialization initiatives, is broadening geographic diversification and building recurring revenue streams. This positions AtriCure to benefit from rising healthcare demand and spending worldwide.

Wonder what the narrative’s boldest financial leap is? The case depends on ambitious revenue climbs and a rare profitability turnaround. Could these projections justify the surge? Find out which aggressive forecasts are pushing this fair value above market consensus and see what lies beneath the headline numbers.

Result: Fair Value of $50 (UNDERVALUED)

However, intensifying competition and regulatory hurdles could slow AtriCure’s growth trajectory. This may challenge both its market share and profitability outlook in coming years.

Another View: Discounted Cash Flow Cautions

The SWS DCF model offers a much more cautious perspective for AtriCure. It estimates fair value at just $0.75, which is significantly below both the current price and analyst targets. Does this sharp disconnect highlight underestimated risks, or could it be overlooking growth potential?

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out AtriCure for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover undervalued stocks based on their cash flows. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Build Your Own AtriCure Narrative

If you have your own perspective or want to dig deeper into the numbers yourself, it only takes a few minutes to craft your own story. Do it your way

A great starting point for your AtriCure research is our analysis highlighting 2 key rewards and 1 important warning sign that could impact your investment decision.

Looking for more investment ideas?

Anyone can follow the crowd. Real investors spot opportunities others overlook. Don’t miss your chance to seize the next big winner by using these tailored stock ideas now:

• Capture high income potential by tapping into these 19 dividend stocks with yields > 3% that outperform savings accounts with proven, reliable yield.
• Spot the future of AI technology when you scan these 27 AI penny stocks at the forefront of machine learning and digital automation.
• Pinpoint stocks trading below their true worth by hunting through these 870 undervalued stocks based on cash flows and give your portfolio a value advantage.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.